China to Keep Working With Russia on Vaccines, Including Mutual Recognition, Ambassador Says

© AP Photo / Pavel GolovkinA vial with Russia's Sputnik V coronavirus vaccine is placed on a table in a medical room at a vaccination center in the GUM, State Department store, in Red Square in Moscow, Russia, Thursday, July 1, 2021.
A vial with Russia's Sputnik V coronavirus vaccine is placed on a table in a medical room at a vaccination center in the GUM, State Department store, in Red Square in Moscow, Russia, Thursday, July 1, 2021. - Sputnik International, 1920, 30.12.2021
Subscribe
International
India
Africa
MOSCOW (Sputnik) - China will keep working with Russia on cooperation issues related to COVID-19 vaccines, including mutual recognition of medicines, Chinese Ambassador to Russia Zhang Hanhui said in an interview with Sputnik.
"Vaccines are an important weapon required to finally defeat the COVID-19 pandemic. China is ready to liaise with other countries, including the Russian side, on cooperation issues related to vaccines against the novel coronavirus, including the mutual recognition of essential vaccines by the two countries, to effectively reduce the risk of cross-border epidemic transmission and promote a new order of healthy, safe and orderly movement of people,” Zhang said.
"Sino-Russian cooperation related to vaccines against the novel coronavirus is close and effective," he said.
A vial labelled Sputnik V coronavirus disease (COVID-19) vaccine is seen in this illustration picture taken on 2 May 2021. - Sputnik International, 1920, 28.12.2021
Russia
Sputnik V Developers to Putin: Trials Show the Russian Vaccine Neutralises Omicron Strain
The ambassador recalled that in November 2020, the third phase of clinical trials of a new recombinant vaccine against coronavirus (Ad5-nCoV) produced by CanSino Biologics was completed in Russia, on the basis of which the vaccine was conditionally allowed for sale in China and is now undergoing the application process for its registration in Russia.
In addition, clinical trials of the third phase of a recombinant novel coronavirus vaccine with fusion protein (V-01) have begun in Russia. The Russian Direct Investment Fund has signed agreements with several Chinese manufacturers to produce in China 150 million doses of Russia's Sputnik V and Sputnik Light vaccines annually, Zhang said.
Newsfeed
0
To participate in the discussion
log in or register
loader
Chats
Заголовок открываемого материала